Translate page

 

Susan BranfordAgnes YONG w labcoat1  

 

                                       

 

Session 2: CML management, Practicalities
Chair: Prof. Tim Hughes

  • Molecular monitoring in CML
    (A/Prof Susan Branford)
  • Allograft - still a role in CML?
    (A/Prof Agnes Yong)

 

 

Susan Branford

 

David Ross David Yeung 3                  

  

Session 3: TFR in CML
Chair: Dr David Ross

  • Monitoring TFR - Challenges 
    (A/Prof Susan Branford)
  • TFR in CML - Clinical Trial Update
    (Dr David Ross)
  • Response definitions and endpoint determination 
    in CML clinical trials
    (Dr David Yeung)

 

 

David Ross

 

Devendra Hiwase Michael Osborn              

 

Session 4: CML Related Topics
Chair: A/Prof Agnes Yong

  • Management of Myelofibrosis
    (Dr David Ross)
  • MDS/MPN Overlap Syndrome
    (Dr Devendra Hiwase)
  • Pediatric CML
    (Dr Michael Osborn)

 

 

Timothy Hughes                            

 

Deborah White Agnes YONG w labcoat1              

 

Session 5: The CML frontier
Chair: Dr David Yeung

  • Making TFR Mainstream
    (Prof. Tim Hughes)
  • Prognostic biomarkers in CML
    (Prof. Deborah White)
  • The immunology of CML and immunomodulation
    (A/Prof Agnes Yong)

 

Presentations from the 23rd Congress of EHA 

We are pleased to make available a couple of presentations on various aspects of CML management that were first presented at the 23rd Congress of the European Hematology Association in Stockholm. Presentations include; treatment options in resistant CML patients, Does IFN-α improve outcome of CML in the TKI era? and TFR - a new goal for CP-CML patients?

 
EHA 2018 Apperley


Treatment options in resistant CML patients
Professor Jane Apperley, Imperial College London, UK 

  • Patient case history 2013 - 2017
  • ELN and NCCN definitions of response and failure
  • Outcome of 'real-life' 1st line imatinib by Sokol
  • Importance of ACA
  • ABL KD mutation sensitivity
  • CCyR rates for sequential use of NIL and DAS after IM failure
  • 3rd line therapy with Bosutinib
  • Relationship of line of therapy to efficacy for PON in 3rd-line vs. 4th line CML
  • SCT for CML: the EBMT score

We are very grateful for the support of Brandcast media to produce these webstreams.

Presentations from the 23rd Congress of EHA 

 
EHA 2018 Nicolini


Does IFN-α improve outcome of CML in the TKI era?
Dr Franck-Emmanuel Nicolini, Centre Hospitalier Universitaire de Lyon, France 

  • LSC persistence on TKI
  • IFN-α anti-tumorigenic activities
  • IFN-α alone and CML: last clinical data
  • What do we know nowadays about the combination of IFN-α and TKI?
  • IFN-α alone as maintenance therapy?
  • Conclusions

 We are very grateful for the support of Brandcast media to produce these webstreams.